Seres Therapeutics Taps Alkermes’s von Moltke as Chief Medical Officer

Seres Therapeutics (NASDAQ: [[ticker:MCRB]]) has appointed Lisa von Moltke to serve as its executive vice president and chief medical officer. She is joining the Cambridge, MA-based microbiome drug developer from Alkermes (NASDAQ: [[ticker:ALKS]]), where she was senior vice president and head of clinical development. Her experience also includes positions at Sanofi (NYSE: [[ticker:SNY]]) and Takeda Pharmaceutical (NYSE: [[ticker:TAK]]). The most advanced Seres program, SER-109, is in Phase 3 testing as a treatment for recurrent Clostridium difficile infection.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.